© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Aerovate Therapeutics, Inc. (AVTE) stock declined over -1.11%, trading at $2.66 on NASDAQ, down from the previous close of $2.69. The stock opened at $2.68, fluctuating between $2.64 and $2.68 in the recent session.
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Employees | 51 |
Beta | 1 |
Sales or Revenue | $0.00 |
5Y Sales Change% | 0% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) stock price is $2.66 in the last trading session. During the trading session, AVTE stock reached the peak price of $2.68 while $2.64 was the lowest point it dropped to. The percentage change in AVTE stock occurred in the recent session was -1.11% while the dollar amount for the price change in AVTE stock was -$0.03.
The NASDAQ listed AVTE is part of Biotechnology industry that operates in the broader Healthcare sector. Aerovate Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Stephen Yu
Senior Vice President of Quality
Dr. Benjamin T. Dake Ph.D.
Founder, Pres, Chief Operating Officer & Sec.
Mr. Stephen K. Yu
Senior Vice President of Quality
Mr. Timothy P. Noyes M.B.A.
Chief Executive Officer & Director
Ms. Susan Fischer
Senior Vice President of Devel. Operations
Ms. Donna Dea
Head of Regulatory Affairs
Dr. Marinus Verwijs Ph.D.
Chief Technical Officer
Mr. Timothy J. Pigot
Chief Commercial Officer
Mr. Hunter Gillies M.D.
Chief Medical Officer
Mr. George A. Eldridge
Chief Financial Officer & Treasurer
Dr. Ralph W. Niven M.B.A., M.R, Ph.D., Pharm.S
Chief Scientific Officer
AVTE's closing price is 115.2% higher than its 52-week low of $1.25 where as its distance from 52-week high of $32.42 is -91.7%.
Number of AVTE employees currently stands at 51.
Official Website of AVTE is: https://aerovatetx.com
AVTE could be contacted at phone 617 443 2400 and can also be accessed through its website. AVTE operates from 930 Winter Street, Waltham, MA 02116, United States.
AVTE stock volume for the day was 2.65K shares. The average number of AVTE shares traded daily for last 3 months was 785.86K.
The market value of AVTE currently stands at $76.81M with its latest stock price at $2.66 and 28.87M of its shares outstanding.